Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging

NCT03503344 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03503344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03503344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
December 17, 2019
Completion date
October 31, 2025
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, psa progression, stage iv prostate adenocarcinoma ajcc v7